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Abstract
Telomerase is a specialized reverse transcriptase that extends and maintains the terminal ends of chromosomes, or telomeres. Since its
discovery in 1985 by Nobel Laureates Elizabeth Blackburn and Carol Greider, thousands of articles have emerged detailing its signifi-
cance in telomere function and cell survival. This review provides a current assessment on the importance of telomerase regulation and
relates it in terms of medical genetics. In this review, we discuss the recent findings on telomerase regulation, focusing on epigenetics
and non-coding RNAs regulation of telomerase, such as microRNAs and the recently discovered telomeric-repeat containing RNA 
transcripts. Human genetic disorders that develop due to mutations in telomerase subunits, the role of single nucleotide polymorphisms
in genes encoding telomerase components and diseases as a result of telomerase regulation going awry are also discussed. Continual
investigation of the complex regulation of telomerase will further our insight into the use of controlling telomerase activity in medicine.
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Introduction
The ends of linear chromosomes are protected from genomic
instability by the DNA-protein complexes known as telomeres [1].
The DNA component of human telomeres comprised a repetitive
TTAGGG sequence (and complimentary sequence on the opposite
strand), up to 20 kb in length, and a 3 G-rich single-stranded
overhang [2, 3]. The G-rich overhang invades the double-stranded
telomeric repeats to form a t-loop, which protects the telomere
from end-to-end fusions and unregulated nuclease digestion of
the 3 overhang [4, 5]. The protein components of human telom-
eres that recognize and bind to the telomeric repeats, such as
Telomeric Repeat Binding Factor 1 and 2, Protection of Telomeres 1,
TRF-Interacting Nuclear Factor-2, Tripeptidyl Peptidase 1, and
Repressor/Activator Protein 1 (TRF1, TRF2, POT1, TIN2, TPP1 and
Rap1), are known as the Shelterin complex which is responsible
for t-loop formation and telomere protection [6, 7].
Telomerase, the specialized enzyme capable of reverse transcrib-
ing DNA, is required for complete replication of telomeres [8]. In
human beings, the core enzyme comprises the protein hTERT,
which contains a reverse transcriptase domain capable of catalysing
the addition of a six nucleotide repeat onto the ends of telomeres
[9], and an RNA component, termed hTR or hTERC (TElomerase
RNA Component), which contains a template region that is comple-
mentary to the human telomere sequence [10]. Telomerase expres-
sion is low or absent in normal human somatic cells, but highly
expressed in embryonic cells, adult male germline cells, in stem
cells of proliferating tissues and over 90% of human malignancies
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[11, 12]. Both hTR and hTERT are significantly up-regulated in
malignant cells compared to normal cell counterparts [13]. Other
telomere/telomerase associated proteins [such as dyskerin,
NucleOlar Protein-10 (NOP10), Non-Histone Protein-2 (NHP2) and
Glycine Arginine Rich-1 (GAR1)] are required for assembly of a
functional telomerase holoenzyme complex [14]. How telomerase is
regulated in expression and activity beyond transcription control
which is covered by several other reviews, and the consequences of
its dysfunction, is the focus of the following sections.
Epigenetic regulation of telomerase:
recent findings beyond transcriptional
control
Regulation of telomerase is very complex as many factors can
effect hTERT expression and telomerase activity. Telomerase may
be regulated through such known methods as transcriptional 
regulation, post-transcriptional regulation, post-translational regu-
lation, localization within the cell, assembly of the subunits, epige-
netic regulation and by telomeric proteins and RNAs [15, 16].
Many new forms of regulation may be yet to be uncovered. In this
section we review recent studies of telomerase regulation involving
methylation of the hTERT promoter and telomeric regions, the pos-
sible role of sirtuins and non-coding RNAs including microRNAs
(miRNAs) and telomeric-repeat containing RNA (TERRA).
Methylation
Regulation of hTERT transcription generally takes place at the pro-
moter region which has been found to contain an abundance of
CpG sites, common targets for methylation [17]. DNA methylation
and chromatin remodelling are common regulators of gene activ-
ity that alter the binding of transcription factors to gene promot-
ers. The field of epigenetics has become very important in the
study of telomerase regulation, and several recent studies have
begun to shed light on some of the factors involved.
A recent study in HPV-induced carcinogenesis has suggested
that a gradual increase in methylation at the hTERT promoter may
coincide with the progression to a tumorigenic phenotype in cer-
vical cell lines, but the effect was not as significant in clinical sam-
ples [18]. This discrepancy may be the result of selection for cells
with greater methylation or, as the authors suggest, may be
caused by the presence of normal tissue in clinical samples,
although it may be related to another complication: researchers
have not been able to agree about whether hTERT methylation fol-
lows the expected relationship. Promoter region methylation is
commonly associated with gene silencing, but studying the epige-
netics affecting the hTERT gene has been difficult. Although some
studies have generated the expected results, other researchers
have indicated that there is no correlation between methylation
and hTERT expression [19]. It has been suggested that methyla-
tion status and its relation to hTERT expression is dependent on
the cell type [20, 21], but there is some debate.
In 2007, Zinn et al. studied multiple cell types to try to deter-
mine if there was some underlying mechanism behind the epige-
netic regulation of telomerase in all cancer types [22]. The group
tested breast, lung and colon cancer samples using methylation-
specific PCR and bisulphite sequencing of the promoter and found
that all of the samples maintained at least one allele with less
methylation around the transcription start site despite surround-
ing methylation patterns. They suggest that although much of the
hTERT promoter may be heavily methylated in some cancer cell
types, a region of about 300 bp around the transcription start site
remains unmethylated and following the usual pattern of methyla-
tion resulting in gene silencing. Although this is an interesting
study providing a possible explanation to the complexity of hTERT
promoter epigenetics, only three tissue types were studied, and
some research suggests that we are still not seeing the whole pic-
ture [20, 23]. Of course, telomerase regulation is complex, and
hTERT promoter methylation is just one piece of the puzzle.
Telomerase activity has also been shown to be subjected to
regulation by methylation of other regions such as the subtelom-
eric region [24]. This is the chromosomal region just proximal to
the telomeric region which has been found to be highly methylated
in mouse and human cells as reviewed previously [24–26]. A
recent study has indicated that subtelomeric methylation may
influence telomerase activity, and specifically whether a tumour
maintains its telomeres with telomerase or through the alternative
lengthening of telomeres (ALT) pathway [27]. The specific mech-
anisms of the ALT pathway are not well known, and it is only uti-
lized by 10–15% of human tumours [28]. Ng et al. analysed sub-
telomeric cytosine methylation, first determining methylation state
in normal cells, and then comparing cells using the ALT pathway
to cells that were telomerase positive. They found that the average
percentage of methylated loci across all normal samples was rel-
atively constant: 81  3%. When analysing ALT cells, the group
found that the amount of methylation varied dramatically, not just
across cell lines, but even across loci. However, when analysing
telomerase positive cells, it was found that all loci were heavily
methylated with little variation: 97  1% [27]. This indicates that
increased methylation of subtelomeric regions may somehow
allow for an increase in telomerase activity, although it is not
known if this is somehow affecting hTERT transcription.
Sirtuins
Recently, work has been done by several groups which suggest
that sirtuins may have a role in telomerase regulation, but findings
have been unclear. Sirtuins are a family of enzymes that have been
shown to play a role in increasing overall health and longevity in
organisms [29]. A study from 2003 by Lin and Elledge suggested
that Sir2 (a yeast protein and the first sirtuin discovered, shown to
increase lifespan by guarding against genome instability [29])
may be an activator of hTERT in a small variety of cancer cell lines
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tested [30]. SIRT1 (NAD-dependent deacetylase sirtuin-1, the human
analogue to Sir2), however, has been suggested to be an inhibitor of
telomerase activity [31]. Likewise, a recent study has shown that
an isoform of P63, NP63, can induce TERT promoter activity 
in mice, and it was suggested that this may be due to the down-
regulation of SIRT1 [32]. Recent studies with resveratrol have also
added to the speculation that SIRT1 may be involved in telomerase
regulation. Resveratrol is one of the most commonly used mole-
cules thought to activate sirtuins. It is a small molecule that has
been shown to improve health and longevity in many of the same
ways as targets of SIRT1 [33]. It has been suggested that resvera-
trol promotes health and longevity by acting through sirtuins,
although this idea is still debated [34, 35]. It has also been shown
that resveratrol activates telomerase in endothelial progenitor cells
[35] and decreases telomerase activity in breast cancer cells [36].
Although it has not been shown that these modifications of telom-
erase activity are directly related to SIRT1 activity, it is an interest-
ing area requiring more study. For more information on current
studies looking into the pharmaceutical use of resveratrol as a
telomerase inhibitor, refer to the section below.
Non-coding RNAs
Little is known about which non-coding RNAs might regulate
telomerase. When studying these factors, the complexity of telom-
erase regulation is compounded by the complex networks of
miRNAs. MicroRNAs, also known as miRNAs or miRs, are non-
coding, single stranded RNAs that have recently been shown to
play critical roles in many biological processes such as develop-
ment, differentiation, apoptosis and proliferation. They commonly
down-regulate the target messenger RNA of protein-coding genes
in a sequence-specific manner [37]. More than 1000 miRNAs are
predicted to work in human biology in a complex regulation net-
work, and several studies have shown that many miRNAs are
deregulated in cancers [37–40]. However, to this day, miRNA reg-
ulation of telomerase remains elusive.
In 2008, Mitomo et al. found an association between the down-
regulation of miR-138 and overexpression of telomerase in
anaplastic thyroid carcinoma cell lines [41]. The researchers
selected miRNAs of interest reported to be differentially expressed
in thyroid carcinoma when compared to normal thyroid. Each
miRNA was studied individually using stem-loop-mediated
reverse transcription real-time PCR. miR-138 was found to be sig-
nificantly down-regulated in anaplastic thyroid carcinoma cell lines
compared to papillary thyroid carcinoma cell lines. Using the miR-
Base online database (http://microrna.sanger.ac.uk), the authors
looked for potential targets of miR-138 and focused on hTERT.
The thyroid carcinoma cell lines were transfected with miR-138
precursor molecules, and effects on hTERT expression were stud-
ied using Western blotting and luciferase assay of the promoter
activity [41]. It is important to note, however, that it has been
shown that many commercially available antibodies used for
Western blotting are not specific to telomerase and may result in
inaccurate conclusions [42]. Although increasing the amount of
miR-138 molecules in the cells did not completely turn off telom-
erase activity in the cell lines studied, this is most likely just the
first of many miRNAs to be associated with telomerase activity.
Also, miRNA activities may be cell-type specific, and the disregu-
lation of miR-138 may be important in telomerase activity in thy-
roid carcinomas, whereas other miRNAs and mechanisms may be
more important in regulating telomerase in other cells and tissues.
It has proven to be a difficult task to pinpoint which miRNAs tar-
get telomerase. Since Motimo et al. 2008 findings, very little head-
way has been made. Although no other specific miRNAs have been
found to date, Miura et al. have found a region of interest that they
believe alters telomerase activity and is most likely to contain a
miRNA precursor gene [43]. Several studies have indicated that
human chromosome 10p may contain a gene involved in regulating
telomerase activity [44–46]. To determine which genes in this
region may be involved, Miura et al. studied the region by exon trap-
ping using bacterial artificial chromosome clones and studied the
effect these segments had on telomerase activity using human
hepatocytes and hepatoma cell lines. One of the genes cloned
(RGM249-RNA gene for miRNAs, 249 bp in length), located at chro-
mosome 10p15.3 was found to be overexpressed in cancer than in
normal liver cells, similar to telomerase expression and was found
to inhibit more than 80% of hTERT mRNA expression [43].
Both the Mitomo and the Miura studies shed light on a small
portion of non-coding RNA molecules that may regulate telom-
erase activity. Both studies utilize relatively new techniques and
technologies which will need to be continually combined and
refined as we continue to study miRNA functions. Telomerase
activity is such an important step in development and cancer pro-
gression that many complex regulatory pathways play a role.
miRNAs have become popular topics of study since their discov-
ery, but even more recently, large non-coding RNAs called TERRA
have been suggested to play a role in telomerase regulation.
Telomeres have long been thought to be transcriptionally silent
regions of the genome. Recently, this notion has been challenged
with the discovery of TERRA, or telomeric repeat-containing RNA,
also called TelRNA [47, 48]. Interestingly, these molecules have
been found to have regulatory effects on telomerase. Mammalian
TERRA molecules are large, non-coding RNA containing UUAGGG
repeats and range in size from 100 bases to about 9 kb [47, 48].
At least some of the TERRA also contain subtelomeric-derived
RNAs well as the telomeric UUAGGG repeats suggesting that tran-
scription of these elements begins at different starting points in
the subtelomeric regions and moves towards the chromosome
ends [47–49]. Relatively little is known about the functions of
TERRA, but they have been shown to be an integral part of telom-
eric heterochromatin [47, 48], and possibly help maintain telom-
ere architecture [49], provide epigenetic protection of telomeres
from DNA repair mechanisms and regulation of telomerase activ-
ity [50]. It is thought that TERRA block telomerase activity at the
telomeres in at least two ways: by blocking the RNA component
with its sequence complementarity [27, 48] and by recruiting het-
erochromatinizing activities to the telomeric regions [48].
Several recent publications have supported the notion that
TERRA molecules may function as telomerase inhibitors.
© 2011 The Authors
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Researchers have found that TERRA are capable of duplexing with
hTERC [48, 50], and it has been shown that there are lower levels
of TERRA molecules in tumours than in corresponding normal
tissue [48, 51]. It has also been found that shorter telomeres have
lower levels of TERRA molecules [48, 50]. Shorter telomeres may
transcribe lower amounts of TERRA because of the decrease in
template space. This would cause less impairment of telomerase
activity and help explain why telomerase has been shown to be
selectively active at critically short telomeres [48, 50].
To further elucidate how transcription of telomeres is regu-
lated and how it might be linked to telomere length, Caslini et al.
have shown that histone 3/lysine 4 (H3/L4) histone methyltrans-
ferase and the transcription regulator Mixed-Lineage Leukemia
(MLL) may contribute to telomere methylation and their transcription
[52]. Local combined activity of H3/L4 and MLL are thought to
promote transcription elongation and chromatin maintenance, but
MLL had not been previously associated with telomeres. Using
ChIP, they found that TTAGGG repeats were capable of pulling
down both the N- and C-terminal domains of MLL in human
haematopoietic cell lines and human ovarian surface epithelium.
The same methods also showed that telomeres were acetylated at
H3 and H4 and to be methylated at H3/K4. It was also shown that
MLL binding positively correlated to H3K4 methylation and tran-
scription of telomeres, and that knocking down MLL resulted in
histone modifications at the telomeres [52].
Interestingly, it has also been shown that there are lower levels
of TERRA transcripts in telomerase positive cells than in cancer
cells that maintain their telomere lengths through the ALT pathway
[27]. Ng et al. compared the levels of TERRA in normal cells, ALT
cells and telomerase positive cells by hybridizing RNA from each
sample set to probes against the UUAGGG TERRA sequence and
the antisense CCCUAA sequence and normalizing to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). They found greater
amounts of TERRA molecules in the ALT cells than any others.
One possibility is that these amounts were higher because ALT
cells have longer telomeres and therefore can transcribe more
TERRA molecules. Taking this into account, the group corrected
for the additional telomeres by measuring telomere lengths in
each sample. ALT cells were still found to have more TERRA tran-
scripts. The group had already shown that telomerase positive
cells have increased methylation at the subtelomeric region com-
pared to normal and ALT cells. It is possible that these two find-
ings are connected and indicate a mechanism in which TERRA
molecule transcription is dampened to allow for more telomerase
activity without hindrance from TERRA in telomerase positive
cells, whereas normal TERRA transcription is allowed in ALT cells.
Consequences of genetic dysfunction
of telomerase: medical genetics of
telomerase
Dysfunction due to mutations in the human genes essential for
telomerase function (TERT and TERC) exhausts the proliferative
capacity of cells with a high turnover rate, such as the
haematopoietic system and other tissues [53]. Extensive work has
shown that telomerase dysfunction and/or telomere shortening
play an important role in the development of bone marrow disor-
ders, such as dyskeratosis congenita (DC) and aplastic anaemia
(AA), and the lung disease idiopathic pulmonary fibrosis (IPF)
[14]. Mutations have been found by amplifying the telomerase
genes of interest and direct sequencing or denaturing HPLC to find
differences between cases and controls (See Table 1 for a sum-
mary list of mutations) [66, 68]. More recently, genome-wide
association studies have found single nucleotide polymorphisms
(SNPs) associated with the diseases [73]. It will be interesting to
see how many more mutations can be found with the new, faster,
more efficient next-generation sequencing becoming more and
more available.
The mutations found thus far are spread throughout hTERC and
hTERT gene sequences, as well as the telomerase-associated pro-
tein dyskerin in the case of DC. The mutations in hTERC affect the
function of telomerase RNA either by disrupting the secondary
structure to prevent its folding into a stable conformation or by
sequence changes that prevent its interaction with other telom-
erase complex components [60]. Two mutations (See Table 1) have
been found in the template region of hTERC, which decrease telom-
erase activity to levels that are undetectable by the Telomeric
Repeat Amplification Protocol (TRAP) assay [55]. The mutations in
hTERT can affect its reverse transcriptase function, DNA-binding
ability and protein–protein interaction strength [74, 75]. hTERT
mutations show varying degrees of effect on telomerase activity,
with both conserved and non-conserved amino acids being able to
drastically reduce activity [59]. Dyskerin interacts with hTR prior to
assembly of the holoenzyme and mutations in Dyskerin 1 (DKC1)
are shown to significantly impair this interaction [76]. hTERT muta-
tions do not show a strict linkage between mutation and disease,
but rather may show an increased risk of disease in individuals with
hTERT mutations. Oppositely, hTERC mutations show a strong
linkage between mutation and disease; however, the correlation
between genotype and phenotype is unclear [77].
Dyskeratosis congenita
DC is a rare multisystem disorder defined by three clinical 
characteristics: oral leukoplakia, nail dystrophy and hyerpigmenta-
tion of the skin [78]. Patients also display signs of premature aging
including hair greying and hair loss, osteoporosis and poor denti-
tion [14]. The vast majority of DC patients (80–90%) develop bone
marrow abnormalities by the age of 30 [79] and bone marrow fail-
ure is the principal cause of early mortality [56]. Individuals with
DC also have a predisposition to cancer with an 11-fold increase in
all cancer types, an 1154-fold increase in frequency of tongue can-
cer, and a 196-fold increase in frequency of acute myeloid
leukaemia (AML) compared to the general population [80].
Mutations in patients suffering from DC were initially discov-
ered in the DKC1 gene (See Table 1) located on the X chromo-
some, which encodes dyskerin, a protein involved in stabilizing
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 15, No 3, 2011
461© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Table 1 Known mutations in DKC1, TERT and TERC involved in human diseases
Disease Gene mutated Domain Type of mutation DNA or protein change Telomerase activity (%) References
DC DKC1 N-terminal Missense A2V NA [54]
P10L NA [55]
Q31K NA [55]
Q31E NA [55]
F36V NA [56]
I38T NA [55]
K39E NA [54]
P40R NA [56]
E41K NA [54]
K43E NA [55]
T49M NA [55]
R65T NA [54]
T66A NA [54]
T67I NA [55]
H68Q NA [55]
L72Y NA [56]
Deletion L37del NA [56]
TruB domain Missense S121G NA [56]
R153W NA [56]
Middle Region Missense S280R NA [56]
PUA domain Missense K314R NA [55]
L317F NA [57]
L321V NA [54]
R322Q NA [57]
M350T NA [54]
M350I NA [54]
A353V NA [54]
T357A NA [55]
D359N NA [55]
C-terminal region Missense P384L NA [56]
P384S NA [56]
A386T NA [55]
L398P NA [55]
G402E NA [56]
G402R NA [54]
T408I NA [55]
P409L NA [55]
S420Y NA [55]
Deletion  from 493 NA [55]
hTERT RT domain Missense P702S 13 [58]
P721R 20–100 [59]
Y846C 10 [58]
H876Q 50 [58]
K902N 0 [59]
Continued
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Table 1 Continued
Disease Gene mutated Domain Type of mutation DNA or protein change Telomerase activity (%) References
C-terminus Missense R979W 20–100 [59]
F1127L 20–100 [59]
hTERC Template Point 48A→G 0 [55]
Deletion 52–55 0 [55]
Near template Point 58G→A 100 [60]
Core pseudoknot Point 37A→G 70 [61]
72 C→G 5 [62]
116C→T 0 [63]
143G→A 0 [62]
Deletion 96–97 0 [62]
Double Point 107–108GC→AG 5 [64]
Hypervariable Deletion 216–229 0 [61]
Point 228G→A 1 [60]
CR4-CR5 Deletion 316–451 ND [62]
H/ACA box Deletion 378–451 5 [64]
Point 408C→G 25 [64]
AA hTERT N-terminus Missense V96L ND [65]
V119L ND [65]
A202T 0 [66]
A279T 20–100 [59]
H412Y 36 [58]
K570N 0 [59]
RT domain Missense G682D 0 [67]
V694M 0 [66]
T726M 20–100 [67]
Y772C 0 [66]
C-terminus Missense V1090M 0 [66]
hTERC Near template Point 58G→A 100 [68]
Core pseudoknot Deletion 28–34 20–100 [59]
79 0 [55]
110–113 0 [68]
Point 72C→G 5 [68]
116C→T 0 [69]
117A→C 0 [69]
204C→G 0 [69]
CR4-CR5 domain Point 228G→A 100 [69]
305G→A 1–2 [69]
H/ACA box Point 450G→A 20–100 [69]
467T→C ND [70]
Continued
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telomerase RNA and forming the enzyme complex [12]. The most
common mutation found in DKC1 is a C→T nucleotide substitu-
tion, which results in the A353V missense mutation in the protein
sequence. This mutation can be inherited or arise de novo [54].
Approximately half of DC patients have a mutation in the genes of
the telomerase holoenzyme complex, hTERT, hTERC or DKC1
[81]. It is likely that the remaining 50% of patients have muta-
tions in other telomere maintenance genes, such as the muta-
tions found in TINF2, NHP2 and NOP10 [82]. The most common
form of the disease shows X-linked inheritance (DKC1 muta-
tions), with 90% of patients being male, although both autosomal
dominant (hTERT, hTERC and TINF2 mutations) and autosomal
recessive (NHP2 and NOP10 mutations) inheritance patterns are
recognized [83, 84].
Aplastic anaemia
AA is another bone marrow failure disease associated with telom-
erase mutations. The disease is rare with an incidence of one to
five per million and defined by hypocellular bone marrow and low
peripheral blood cell counts [63]. A few patients who initially pre-
sented with AA have been found to develop DC, suggesting that
AA is a marker of more severe phenotypes [68]. The observation
that AA patient leucocytes had significantly shorter telomeres than
controls led researchers to screen patients for mutations in telom-
erase components [53]. In acquired AA, approximately 2.5% of
patients have mutations in hTERC and 3.5% have mutations in
hTERT (See Table 1 for list) [66]. The majority of hTERC mutations
cluster in the pseudoknot region, which is essential for hTERT
binding and telomerase enzymatic activity [53]. The identified
hTERT mutations are spread throughout the gene and act by 
haploinsufficiency, not a dominant negative mechanism. hTERC
mutations decrease telomerase activity through haploinsufficiency
as well [66].
Idiopathic pulmonary fibrosis
IPF is a much more common disease, with a prevalence of at least
90,000, than DC or AA, although the aetiology of the disease is
unclear, as implied by idiopathic [85]. The clinical course of IPF is
progressive and predictable, beginning with massive fibrotic
changes and alveolar wall thickening in the lungs and patients ulti-
mately succumbing to respiratory failure [72, 73]. One in five
patients with IPF has a family history of the disease and inheri-
tance looks to be autosomal dominant with variable penetrance
[53]. In patients with a documented family history of IPF, hTERC
and hTERT mutations account for 8–15% of disease inheritance
[86]. Sporadic IPF has detectable telomerase mutations in 1–3%
of cases. Although the percentage of patients with telomerase
mutations is lower in IPF than dyskeratosis congentia, the higher
incidence rate makes pulmonary fibrosis the most common clinical
manifestation of telomerase gene mutations [85]. There are fifteen
known mutations in hTERT and only two in hTERC (See Table 1);
moreover, the mutations do not appear to cluster in any region or
domain of either gene. IPF patients without telomerase mutations
also have short telomeres when compared to controls, suggesting
that telomere length, rather than telomerase mutations, is a better
predictor of disease onset [86].
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Table 1 Continued
Disease Gene mutated Domain Type of mutation DNA or protein change Telomerase activity (%) References
IPF hTERT N-terminus Missense P33S 80 [71]
L55Q 40 [72]
V144M 78 [71]
R486C 45 [71]
Deletion 112C ND [72]
RT Domain Frameshift del V747fs 2 [71]
Missense R865C 20 [71]
R865H 28 [71]
C-terminus Missense T1110M 50 [72]
Frameshift del E1116fs 6 [71]
Intron Point Intron 1 1 G→A ND [72]
Point Intron 9–2 A→C ND [72]
hTERC Core pseudoknot Point 37A→G 70 [71]
Point 98G→A 10 [12]
For further review, see http://telomerase.asu.edu/diseases.html.
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Acute myeloid leukaemia
Due to AA patients with telomerase mutations often having a fam-
ily history of AML and patients suffering from AA and DC having a
predisposition to AML, researchers looked for and found telom-
erase mutations in AML patients [87]. AML is a heterogeneous
disease due to an acquired somatic mutation in the myeloid line-
age of a haematopoietic progenitor cell [88]. Nearly half of AML
patients have abnormal karyotypes and genomic instability plays a
crucial role in leukemogenesis [87]. Calado et al. recently reported
that 6.8% of patients with AML had mutations in hTERT and no
mutations were found in hTERC. The A1062T hTERT mutation was
found to be the most common variant between cases and controls
and constituted 60% of all hTERT mutations found in AML
patients [87]. Kirwan et al. have expanded on this work and found
another hTERT mutation and two hTERC mutations in familial
forms of AML [89]. The A1062T mutation has been found in mul-
tiple haematopoietic cancers and may serve as a surrogate marker
for mutations throughout hTERT as a screening tool to identify
other malignancies with telomerase as a predisposing factor [12].
TERT and TERC variations and disease
predisposition
Although mutations in telomerase have been found to have impor-
tant implications in growth and development, naturally occurring
variations in hTERT and hTERC remain to be fully understood.
These SNPs are limited and telomerase genes express less het-
erozygosity compared to other genes further demonstrating the
overall importance of these genes [80, 90]. hTERT is located
within a locus at chromosome 5p13.33 and hTERC is located
within a locus at chromosome 3q26. Given the presence of telom-
erase activity in haematopoietic stem cells, it is likely that varia-
tions and/or mutations in the telomerase components would have
significant implications for haematopoiesis. In fact, defects in
telomerase function contribute to disease pathogenesis particu-
larly in bone-marrow failure syndromes [91]. Studies have also
identified an association between telomerase mutations in both
hTERC and hTERT with familial myelodysplastic syndrome and
AML as mentioned previously [12, 89]. In addition to the
haematopoietic cell compartment, tissue based stem cells might
also be affected by variations in telomerase.
Variations in the genes required to form the active telomerase
complex may contribute to cancer risk. The correlation between
telomerase function and cancer is most likely due to the fact that
tumour formation can be driven by telomerase dysfunction.
Immortalization of tumour cells can occur through hTERT gene
rearrangement which may contribute to cancer risk if variations in
telomerase promote gene rearrangement and telomerase activation
[92]. It is also probable that failure to stabilize telomeres prior to
significant shortening could contribute to an increased genomic
instability capable of promoting increased tumour development and
progression [80]. Variations in hTERC and hTERT have been found
to contribute to overall telomere length implying a potential role for
these variations in cancer risk [93, 94]. Recent genome-wide asso-
ciation studies have been performed in order to define whether
there is an association between telomerase SNPs and cancer risk.
There is conflicting data regarding the role of hTERT variations
and increased risk of breast cancer [80]. Although some studies
have found an association between breast cancer risk and telom-
erase SNP [90], the most compelling data involve studies per-
formed on a total of 1656 breast cancer samples and 2019
matched controls [95]. These compelling, high power studies did
not find an association between increased breast cancer risk and
the SNPs of the telomerase promoter [95, 96]. In line with these
findings, Pooley et al. did not observe a strong association of the
SNP rs401681 in the TERT-CLPTM1L locus with cancer risk,
related to telomere length [97].
Although breast cancer risk does not appear to be associated
with telomerase SNPs, other studies have demonstrated a change
in cancer risk associated with hTERC and hTERT variations. For
example, variation in the TERT-CLPTM1L genes was found to be
associated with a decreased risk of squamous cell carcinoma of
the head and neck [98]. Although a decreased risk was observed
in this study, other studies have found an association for this
region (5p15.33) and increased cancer risk. Additional genome-
wide association studies found this region to be associated with
increased risk for both pancreatic cancer and lung adenocarci-
noma [99–104]. Unlike the studies involving breast cancer, an
increased risk of prostate cancer was found to be associated with
at least one hTERT variation that influences telomerase expression
[105, 106]. Other studies have linked cancer risk and telomerase
SNP for several cancers including the following: bladder cancer
[106, 107], ovarian cancer [108] and cervix cancer [106].
But, what do these reported associations mean? What is the
functional consequence of a SNP/variant in hTERT or hTERC? It is
known that telomerase is tightly controlled and complex; muta-
tions or haploinsufficiency of hTERT/hTERC drive telomere dys-
function and bone marrow failures that are detrimental to the
organism’s survival. More research is needed to determine
whether a variant in the hTERT promoter could alter the ability of
a repressor to bind and maintain its tight control over its transcrip-
tion and ultimately activity. Loss of such repression could impact
telomere maintenance, immortality, and progression of precancer-
ous lesions. Furthermore, could a SNP in hTERC slightly alter
structure of the RNA which in turn affects telomerase activity and
telomere maintenance? These are questions arising by the obser-
vations of the medical geneticists for the telomerase/telomere
biology field to address in the laboratory.
Summary and perspectives
Telomerase regulation is complex and has important consequences
not just for telomere length, but also for the development of disease.
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Obtaining further insight into the role of telomerase gene regulation
and therefore telomerase activity in disease development will serve
to assist in the generation of enhanced therapies. Understanding
how telomerase is regulated will also lead to improved targeting of
telomerase as a therapy for genetic diseases and cancer.
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